Piehl F - Search Results

1

Rituximab treatment for multiple sclerosis.

Ineichen BV, Moridi T, Granberg T, Piehl F. Ineichen BV, et al. Among authors: piehl f. Mult Scler. 2020 Feb;26(2):137-152. doi: 10.1177/1352458519858604. Epub 2019 Jun 25. Mult Scler. 2020. PMID: 31237800

2

Reduction of both pro- and anti-inflammatory cytokines after 6 months of interferon beta-1a treatment of multiple sclerosis.

Khademi M, Wallström E, Andersson M, Piehl F, Di Marco R, Olsson T. Khademi M, et al. Among authors: piehl f. J Neuroimmunol. 2000 Mar 1;103(2):202-10. doi: 10.1016/s0165-5728(99)00184-8. J Neuroimmunol. 2000. PMID: 10696916 Clinical Trial.

3

The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers.

Khademi M, Bornsen L, Rafatnia F, Andersson M, Brundin L, Piehl F, Sellebjerg F, Olsson T. Khademi M, et al. Among authors: piehl f. Eur J Neurol. 2009 Apr;16(4):528-36. doi: 10.1111/j.1468-1331.2009.02532.x. Eur J Neurol. 2009. PMID: 19220425

4

Swedish natalizumab (Tysabri) multiple sclerosis surveillance study.

Piehl F, Holmén C, Hillert J, Olsson T. Piehl F, et al. Neurol Sci. 2011 Jan;31 Suppl 3:289-93. doi: 10.1007/s10072-010-0345-y. Neurol Sci. 2011. PMID: 20556456

5

High levels of 15-oxygenated steroids in circulation of patients with multiple sclerosis: fact or fiction?

Björkhem I, Lövgren-Sandblom A, Piehl F, Khademi M, Pettersson H, Leoni V, Olsson T, Diczfalusy U. Björkhem I, et al. Among authors: piehl f. J Lipid Res. 2011 Jan;52(1):170-4. doi: 10.1194/jlr.D011072. Epub 2010 Oct 7. J Lipid Res. 2011. PMID: 20934989 Free PMC article.

6

Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.

Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg F, Hillert J, Piehl F, Olsson T. Khademi M, et al. Among authors: piehl f. Mult Scler. 2011 Mar;17(3):335-43. doi: 10.1177/1352458510389102. Epub 2010 Dec 6. Mult Scler. 2011. PMID: 21135023

7

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.

Holmén C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, Nilsson P, Dahle C, Feltelius N, Svenningsson A, Lycke J, Olsson T. Holmén C, et al. Among authors: piehl f. Mult Scler. 2011 Jun;17(6):708-19. doi: 10.1177/1352458510394701. Epub 2011 Jan 12. Mult Scler. 2011. PMID: 21228027

8

The expression of VEGF-A is down regulated in peripheral blood mononuclear cells of patients with secondary progressive multiple sclerosis.

Iacobaeus E, Amoudruz P, Ström M, Khademi M, Brundin L, Hillert J, Kockum I, Malmström V, Olsson T, Tham E, Piehl F. Iacobaeus E, et al. Among authors: piehl f. PLoS One. 2011 May 6;6(5):e19138. doi: 10.1371/journal.pone.0019138. PLoS One. 2011. PMID: 21573104 Free PMC article.

9

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

Tedeholm H, Lycke J, Skoog B, Lisovskaja V, Hillert J, Dahle C, Fagius J, Fredrikson S, Landtblom AM, Malmeström C, Martin C, Piehl F, Runmarker B, Stawiarz L, Vrethem M, Nerman O, Andersen O. Tedeholm H, et al. Among authors: piehl f. Mult Scler. 2013 May;19(6):765-74. doi: 10.1177/1352458512463764. Epub 2012 Nov 1. Mult Scler. 2013. PMID: 23124789 Free PMC article.

10

Multiple sclerosis risk genotypes correlate with an elevated cerebrospinal fluid level of the suggested prognostic marker CXCL13.

Lindén M, Khademi M, Lima Bomfim I, Piehl F, Jagodic M, Kockum I, Olsson T. Lindén M, et al. Among authors: piehl f. Mult Scler. 2013 Jun;19(7):863-70. doi: 10.1177/1352458512463482. Epub 2012 Nov 22. Mult Scler. 2013. PMID: 23175382

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

362 results

Search Page